Bentyl (Dicyclomine) - Clinical Overview
Bentyl (dicyclomine) is an antispasmodic agent indicated for irritable bowel syndrome (IBS) that works through dual anticholinergic and direct smooth muscle relaxant mechanisms to reduce abdominal pain and gastrointestinal spasm. 1
Primary Indication
- IBS-associated abdominal pain and spasm - The American Gastroenterological Association (AGA) conditionally recommends antispasmodics including dicyclomine for patients with IBS, though the evidence quality is low. 1
- Dicyclomine is one of only three antispasmodics (along with hyoscine and peppermint oil) available in the United States for this indication. 1
- In controlled trials, 82% of patients treated with dicyclomine 160 mg daily (40 mg four times daily) showed favorable clinical response compared to 55% with placebo (p<0.05). 2
Mechanism of Action
Dicyclomine provides dual-action relief: 2
- Anticholinergic effect - Blocks acetylcholine at muscarinic receptors with approximately 1/8 the potency of atropine
- Direct musculotropic effect - Acts directly on smooth muscle, antagonizing bradykinin and histamine-induced spasms
Dosing
Standard adult dosing for IBS: 2, 3
- Initial dose: 40 mg four times daily (160 mg/day total)
- Dose adjustment: If side effects occur, reduce to an average of 90 mg daily while maintaining clinical benefit
- Timing: Rapid absorption occurs after oral administration, reaching peak levels within 60-90 minutes 2
- Elimination: Half-life approximately 1.8 hours; primarily excreted in urine (79.5%) 2
Absolute Contraindications
Dicyclomine is contraindicated in: 2
- Obstructive uropathy
- Obstructive gastrointestinal disease
- Severe ulcerative colitis
- Reflux esophagitis
- Unstable cardiovascular status in acute hemorrhage
- Glaucoma
- Myasthenia gravis
- Infants less than 6 months of age
- Nursing mothers
- Known hypersensitivity to dicyclomine
Common Side Effects
The most frequently reported adverse effects are anticholinergic in nature: 2
- Dry mouth - 33% (vs 5% placebo)
- Dizziness - 29% (vs 2% placebo)
- Blurred vision - 27% (vs 2% placebo)
- Nausea - 14% (vs 6% placebo)
- Light-headedness - 11% (vs 3% placebo)
- Drowsiness - 9% (vs 1% placebo)
Important: 9% of patients discontinued treatment due to side effects, though in 41% of patients experiencing side effects, these either disappeared or were tolerated at the full 160 mg daily dose. 2
Critical Safety Considerations
- Never administer intravenously - IV administration can cause thrombosis due to M3 receptor inhibition leading to nitric oxide suppression and subsequent clotting. 4
- Use caution in constipation-predominant IBS - Regular use may be limited due to anticholinergic effects that can worsen constipation. 1
- No serious adverse events were reported in the Cochrane Review of antispasmodics for IBS. 1
Clinical Context
While the AGA's recommendation for antispasmodics is conditional with low-certainty evidence, dicyclomine remains commonly used in clinical practice for IBS-related abdominal pain. 1 The evidence base includes considerable variation in diagnostic criteria, dosing schedules, and endpoints across studies, but meta-analysis shows significant improvement in both global IBS symptoms (RR 0.67; 95% CI 0.55-0.80) and abdominal pain (RR 0.74; 95% CI 0.59-0.93) compared to placebo. 1